Ina Møller
Background and activities
Courses
- HBIO3001 - Bachelor thesis in Biomedical Laboratory Science
- HBIOT2025 - Medical laboratory technology: quality assesment, validation of methods and statistics
- HBIO2006 - Medical Laboratory Technology 4, Immunological-, Cytological- and Histological Techniques
- HBIO3004 - Medical Laboratory Technology 5B, Immunohematology
- HBIO3005 - Medical Laboratory Technology 6, Medical Biochemistry, Microbiology and Pathology
- HBIOT2024 - Medical Laboratory Technology - Histological- and Immunological Techniques and Cytology
- HBIOT2021 - Medical Laboratory Technology: Quantification Techniques
Scientific, academic and artistic work
A selection of recent journal publications, artistic productions, books, including book and report excerpts. See all publications in the database
Journal publications
- (2018) Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. Alzheimer's Research & Therapy. vol. 10:9.
- (2018) The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease. Acta neuropathologica communications. vol. 6.
- (2017) Cerebrospinal fluid levels of amyloid beta 1-43 mirror 1-42 in relation to imaging biomarkers of Alzheimer's disease. Frontiers in Aging Neuroscience. vol. 9.
- (2017) Cerebrospinal fluid Aβ43 is reduced in early-onset compared to late-onset Alzheimer's disease, but has similar diagnostic accuracy to Aβ42. Frontiers in Aging Neuroscience. vol. 9 (210).
- (2016) Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study. BMC Neurology. vol. 16 (180).
- (2016) Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. Frontiers in Aging Neuroscience. vol. 8.
- (2015) Effect of tween-20 on core biomarkers measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy control individuals. Journal of Alzheimer's Disease. vol. 49 (2).